Global Hemophilia Market Predicted To Augment At A CAGR Of Around 6.58% During 2024-2032

As per analysts at Zion Market Research, the global Hemophilia Market, estimating its value at USD 13.01 Billion in 2023, with projections indicating that it will reach USD 23.08 Billion by 2032. The market is expected to expand at a compound annual growth rate (CAGR) of 6.58% over the forecast period 2024-2032. Certain aspects that are propelling the market growth are growing incidence of hemophilia, favorable administrative initiatives, and surging research & development for new product development. Hemophilia is a genetic disorder in which the blood clotting ability is severely reduced and usually affects 1 in 5,000 male births. Approximately, 410 babies are born with hemophilia every year in the U.S. As per the WFH (World Federation of Hemophilia), around 184,723 people were affected with hemophilia during 2016. Likewise as per the WHO (World Health Organization), due to the sex-linkage of the disorder, there is greater prominence in males compared to females.

Some of the key players in the market are BioMarin Pharmaceutical, Inc.; Bayer AG; Kedrion; CSL Behring; Pfizer, Inc.; Novo Nordisk; Sanofi (Genzyme Corporation); Roche (Chugai Pharmaceutical Co.); and Takeda Pharmaceutical (Shire Plc.).

Growing Incidence Of Hemophilia Around The World To Stimulate The Global Hemophilia Market

The growing incidence of hemophilia globally is one of the main market augmenting factors during the forecasted period. According to the statistics published by CDC (Centers for Disease Control and Prevention), hemophilia A affects almost 1 in 5,000 male births in the U.S. Most of the people having hemophilia are identified at a young age. As per the CDC information, the average age of hemophilia identification in the U.S. is 1 month for severe hemophilia, 8 months for moderate hemophilia, and36 months for mild hemophilia. Therefore, a surge in the number of people suffering from hemophilia is expected to enhance the hemophilia treatment market development in the future. The rise in a number of administrative initiatives will boost the industry growth over the forecasted period.

The global hemophilia market is bifurcated on the basis of disease type, therapy, product type, and regional analysis. Based on the disease type, the market is divided into hemophilia A, hemophilia B, and others. Based on the therapy, the market is divided into gene therapy, replacement therapy, and others (immune tolerance induction therapy). Based on the product type, the market is divided into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, and others (desmopressin).

North America Expected To Dominate The Global Hemophilia Market In The Forecast Period

Based on geographical analysis, the global hemophilia market is divided into Latin America, North America, Middle East & Africa, Asia Pacific, and Europe. NHF (National Hemophilia Foundation) awards fellowships & grants so as to support innovative research planned for discovering better treatments and cures for many bleeding disorders. Such scientists have led to fundamental insights into better factor replacement therapies, coupled with more precise hemophilia diagnostic techniques and therefore certainly a greater perceptive of the genetic basis of the disease. For long, NHF has been involved in developing the standard of clinical care and issuing treatment suggestions for hemophilia. NHF noted that the number of people having hemophilia in the U.S. is anticipated to be around 20,000 individuals in 2019. Therefore, due to the increasing prevalence of the disease coupled with the growing initiatives by many organizations is fueling the market growth in the region.

Browse the full “Hemophilia Market - By Disease Type (Hemophilia A, Hemophilia B, and Others), By Therapy (Gene Therapy, Replacement Therapy, and Others), By Product Type (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, and Others), And By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2025.” Report at https://www.zionmarketresearch.com/report/hemophilia-market

The global hemophilia market is segmented as follows:

By disease type:

• Hemophilia A
• Hemophilia B
• Others

By therapy:

• Replacement Therapy
• Gene Therapy
• Others (Immune Tolerance Induction Therapy etc.)

By product type:

• Recombinant Coagulation Factor Concentrates
• Plasma-derived Coagulation Factor Concentrates
• Others (Desmopressin etc.)

By region:                

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com